stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Total debt
BeOne Medicines Ltd. - Sponsored ADR's total debt at the end of fiscal 2025 was $961.9M, up 477.8% from $166.5M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $825.2M. Over the past ten years it has ranged from $6.2M (fiscal 2015) to $961.9M (fiscal 2025) — the current reading is the highest in ten years. BeOne Medicines Ltd. - Sponsored ADR ranks 17th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $961.9M | 477.78% |
| FY2024 | $166.5M | (15.75%) |
| FY2023 | $197.6M | (63.28%) |
| FY2022 | $538.1M | (17.38%) |
| FY2021 | $651.3M | 22.28% |
| FY2020 | $532.7M | 111.82% |
| FY2019 | $251.5M | 26.75% |
| FY2018 | $198.4M | 20.45% |
| FY2017 | $164.7M | 852.99% |
| FY2016 | $17.3M | 179.31% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $825.2M | (6.45%) |
| Jun 2026 | $882.2M | (8.35%) |
| Mar 2026 | $962.5M | 0.06% |
| Dec 2025 | $961.9M | 589.19% |
| 41 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $8.6B |
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| RVMD Revolution Medicines, Inc. compare | $1.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR | $825.2M |
| INSM Insmed, Inc. compare | $562.8M |
| BNTX BioNTech SE Sponsored ADR compare | $414.1M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| INCY Incyte Corporation compare | $27.6M |
| ARGX argenex SE compare | $7.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement